{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:59:58Z","timestamp":1791849598819,"version":"4.3.4"},"reference-count":143,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:p>The American Diabetes Association (ADA) \u201cStandards of Medical Care in Diabetes\u201d includes ADA\u2019s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA\u2019s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org\/SOC.<\/jats:p>","DOI":"10.2337\/dc18-s010","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T16:20:19Z","timestamp":1512750019000},"page":"S105-S118","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":259,"title":["10. Microvascular Complications and Foot Care:\n                    <i>Standards of Medical Care in Diabetes\u20142018<\/i>"],"prefix":"10.2337","volume":"41","author":[{"name":"American Diabetes Association","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"2022031220110196500_B1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B2","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"National Kidney Foundation","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2022031220110196500_B3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2022031220110196500_B4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"2022031220110196500_B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"37","author":"de Boer","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B6","volume-title":"Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2016"},{"key":"2022031220110196500_B7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2022031220110196500_B8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022031220110196500_B9","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"key":"2022031220110196500_B10","first-page":"17","article-title":"An age-calibrated definition of chronic kidney disease: rationale and benefits","volume":"37","author":"Delanaye","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"2022031220110196500_B11","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"2022031220110196500_B12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/dc09-1098","article-title":"Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study","volume":"33","author":"Molitch","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00125-012-2796-6","article-title":"Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis","volume":"56","author":"He","year":"2013","journal-title":"Diabetologia"},{"key":"2022031220110196500_B14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022031220110196500_B15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2015.02.338","article-title":"A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury","volume":"66","author":"James","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022031220110196500_B16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B18","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2215\/CJN.01120211","article-title":"Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus","volume":"6","author":"Thakar","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031220110196500_B19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2215\/CJN.06290616","article-title":"The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals","volume":"12","author":"Hughes-Austin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031220110196500_B20","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022031220110196500_B21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022031220110196500_B22","first-page":"1969","article-title":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: The DCCT\/EDIC study","volume-title":"Clin J Am Soc Nephrol","author":"de Boer","year":"2016"},{"key":"2022031220110196500_B23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02720317","article-title":"Changes in albuminuria and subsequent risk of incident kidney disease","volume-title":"Clin J Am Soc Nephrol","author":"Sumida"},{"key":"2022031220110196500_B24","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1001\/jama.2016.4447","article-title":"Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease","volume":"315","author":"Mills","year":"2016","journal-title":"JAMA"},{"key":"2022031220110196500_B25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"DCCT\/EDIC Research Group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031220110196500_B26","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B27","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031220110196500_B28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031220110196500_B29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"2022031220110196500_B31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031220110196500_B33","first-page":"b5444","article-title":"ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study","volume-title":"BMJ","author":"Miller","year":"2010"},{"key":"2022031220110196500_B34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"2022031220110196500_B35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"2022031220110196500_B36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2022031220110196500_B38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031220110196500_B39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022031220110196500_B40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","article-title":"Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes","volume":"66","author":"Cooper","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022031220110196500_B43","first-page":"839","article-title":"LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes","volume-title":"N Engl J Med","author":"Mann","year":"2017"},{"key":"2022031220110196500_B44","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease","author":"Wanner","journal-title":"Circulation"},{"key":"2022031220110196500_B47","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet], 2016. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm. Accessed 14 October 2016"},{"key":"2022031220110196500_B48","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.02850315","article-title":"BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes Trial","volume":"10","author":"Leehey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031220110196500_B49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2022031220110196500_B50","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"2022031220110196500_B52","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B54","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B55","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"2022031220110196500_B57","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B58","doi-asserted-by":"crossref","first-page":"e0177654","DOI":"10.1371\/journal.pone.0177654","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"2022031220110196500_B59","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B60","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"key":"2022031220110196500_B61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B63","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B64","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B65","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022031220110196500_B66","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022031220110196500_B67","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2022031220110196500_B68","first-page":"CD007333","article-title":"Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease","volume":"6","author":"Smart","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220110196500_B69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B70","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/diacare.18.2.258","article-title":"Hyperglycemia and microvascular and macrovascular disease in diabetes","volume":"18","author":"Klein","year":"1995","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/ajkd.1998.v31.pm9631838","article-title":"Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM","volume":"31","author":"Estacio","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2022031220110196500_B72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ophtha.2004.11.054","article-title":"Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies","volume":"112","author":"Leske","year":"2005","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B73","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B74","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B76","first-page":"137","article-title":"Effects of prior intensive insulin therapy and risk factors on patient-reported visual function outcomes in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) cohort","volume-title":"JAMA Ophthalmol","author":"Gubitosi-Klug","year":"2016"},{"key":"2022031220110196500_B77","doi-asserted-by":"crossref","first-page":"E148","DOI":"10.1503\/cmaj.150771","article-title":"Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy","volume":"188","author":"Shih","year":"2016","journal-title":"CMAJ"},{"key":"2022031220110196500_B78","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","article-title":"Diabetic retinopathy","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B79","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","article-title":"Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial","volume":"23","author":"Diabetes Control and Complications Trial Research Group","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B80","first-page":"825","article-title":"SEARCH for Diabetes in Youth Research Group. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume-title":"JAMA","author":"Dabelea","year":"2017"},{"key":"2022031220110196500_B81","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc10-2308","article-title":"Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy","volume":"34","author":"Agardh","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B82","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1612836","article-title":"Frequency of evidence-based screening for retinopathy in type 1 diabetes","volume":"376","author":"Nathan","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031220110196500_B83","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archophthalmol.2010.319","article-title":"Screening for presence or absence of diabetic retinopathy: a meta-analysis","volume":"129","author":"Bragge","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"2022031220110196500_B84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaophthalmol.2015.5083","article-title":"Evaluation of automated teleretinal screening program for diabetic retinopathy","volume":"134","author":"Walton","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2022031220110196500_B85","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/dc06-0295","article-title":"The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy","volume":"29","author":"Ahmed","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B86","first-page":"S1","article-title":"Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy","volume-title":"Can J Ophthalmol","author":"Hooper","year":"2012"},{"key":"2022031220110196500_B87","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0161-6420(96)30421-1","article-title":"Diabetic retinopathy during pregnancy","volume":"103","author":"Axer-Siegel","year":"1996","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/bjo.81.3.249","article-title":"Diabetic retinopathy in pregnancy","volume":"81","author":"Best","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"2022031220110196500_B89","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.2337\/db07-1024","article-title":"A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for glycemia before conception: the Coronary Artery Risk Development in Young Adults (CARDIA) Study","volume":"56","author":"Gunderson","year":"2007","journal-title":"Diabetes"},{"key":"2022031220110196500_B90","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy","volume":"81","author":"The Diabetic Retinopathy Study Research Group","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"2022031220110196500_B91","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"2022031220110196500_B92","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"2022031220110196500_B93","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B94","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B95","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B96","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"2022031220110196500_B97","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11892-014-0528-7","article-title":"Glucose control and diabetic neuropathy: lessons from recent large clinical trials","volume":"14","author":"Ang","year":"2014","journal-title":"Curr Diab Rep"},{"key":"2022031220110196500_B98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B99","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11892-009-0069-7","article-title":"Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy","volume":"9","author":"Freeman","year":"2009","journal-title":"Curr Diab Rep"},{"key":"2022031220110196500_B101","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B102","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2012.10.028","article-title":"Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT\/EDIC study (Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications)","volume":"61","author":"Pop-Busui","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022031220110196500_B103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jdiacomp.2014.02.013","article-title":"The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy","volume":"28","author":"Smith","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031220110196500_B104","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ana.410380607","article-title":"Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial","volume":"38","author":"Diabetes Control and Complications Trial (DCCT) Research Group","year":"1995","journal-title":"Ann Neurol"},{"key":"2022031220110196500_B105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s001250050924","article-title":"The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)","volume":"41","author":"CDC Study Group","year":"1998","journal-title":"Diabetologia"},{"key":"2022031220110196500_B106","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","article-title":"Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study","volume":"33","author":"Albers","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B107","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation"},{"key":"2022031220110196500_B108","first-page":"CD007543","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"6","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220110196500_B109","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DMSO.S37415","article-title":"Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey","volume":"6","author":"Sadosky","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031220110196500_B111","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/WNL.0000000000003882","article-title":"Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review","volume":"88","author":"Waldfogel","year":"2017","journal-title":"Neurology"},{"key":"2022031220110196500_B112","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"2022031220110196500_B113","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction in Neurology 2011;77:603]","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"2022031220110196500_B114","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/M14-0511","article-title":"Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis","volume":"161","author":"Griebeler","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022031220110196500_B115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jdiacomp.2014.08.008","article-title":"From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy","volume":"29","author":"Ziegler","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2022031220110196500_B116","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc07-2105","article-title":"Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses","volume":"31","author":"Freeman","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"2022031220110196500_B117","first-page":"CD007076","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220110196500_B118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/AJP.0b013e31829ea1a1","article-title":"Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial","volume":"30","author":"Raskin","year":"2014","journal-title":"Clin J Pain"},{"key":"2022031220110196500_B119","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"2022031220110196500_B120","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/j.pain.0000000000000263","article-title":"A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain","volume":"156","author":"Ziegler","year":"2015","journal-title":"Pain"},{"key":"2022031220110196500_B121","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"2022031220110196500_B122","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpain.2006.06.005","article-title":"Symptom profiles differ in patients with neuropathic versus non-neuropathic pain","volume":"8","author":"Dworkin","year":"2007","journal-title":"J Pain"},{"key":"2022031220110196500_B123","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology"},{"key":"2022031220110196500_B124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/dc06-0947","article-title":"Does treatment with duloxetine for neuropathic pain impact glycemic control?","volume":"30","author":"Hardy","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022031220110196500_B126","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2337\/dc13-2291","article-title":"A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis","volume":"108","author":"Camilleri","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022031220110196500_B128","volume-title":"Therapy for Diabetes Mellitus and Related Disorders","author":"Umpierrez","year":"2014","edition":"6th ed"},{"key":"2022031220110196500_B129","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B130","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2015.10.003","article-title":"The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine","volume":"63","author":"Hingorani","year":"2016","journal-title":"J Vasc Surg"},{"key":"2022031220110196500_B131","doi-asserted-by":"crossref","first-page":"29758","DOI":"10.3402\/dfa.v7.29758","article-title":"Type 2 diabetes-related foot care knowledge and foot self-care practice interventions in the United States: a systematic review of the literature","volume":"7","author":"Bonner","year":"2016","journal-title":"Diabet Foot Ankle"},{"key":"2022031220110196500_B132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1534734612438729","article-title":"Custom-made orthesis and shoes in a structured follow-up program reduces the incidence of neuropathic ulcers in high-risk diabetic foot patients","volume":"11","author":"Rizzo","year":"2012","journal-title":"Int J Low Extrem Wounds"},{"key":"2022031220110196500_B133","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022031220110196500_B134","first-page":"46S","article-title":"A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers","volume-title":"J Vasc Surg","author":"Elraiyah","year":"2016"},{"key":"2022031220110196500_B135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/dmrr.2707","article-title":"Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review","volume":"32","author":"Game","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"2022031220110196500_B136","first-page":"CD004123","article-title":"Hyperbaric oxygen therapy for chronic wounds","author":"Kranke","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220110196500_B137","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc09-1754","article-title":"Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes","volume":"33","author":"L\u00f6ndahl","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B138","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/dc15-2001","article-title":"Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: a prospective, double-blind, randomized controlled clinical trial","volume":"39","author":"Fedorko","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031220110196500_B139","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00592-017-1012-z","article-title":"Relationship between hyperbaric oxygen therapy and quality of life in participants with chronic diabetic foot ulcers: data from a randomized controlled trial","volume":"54","author":"Li","year":"2017","journal-title":"Acta Diabetol"},{"key":"2022031220110196500_B140","unstructured":"Boulton\u2008AJM. The Diabetic Foot [Internet], 2000. South Dartmouth, MA, MDText.com, Inc. Available from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409609\/. Accessed 5 October 2017"},{"key":"2022031220110196500_B141","first-page":"1","article-title":"Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: a health technology assessment","volume":"17","author":"Health Quality Ontario","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"key":"2022031220110196500_B142","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0654","article-title":"Hyperbaric oxygen therapy in the treatment of ischemic lower extremity ulcers in patients with diabetes: results of the DAMO2CLES multicenter randomized clinical trial.","author":"Santema","journal-title":"Diabetes Care."},{"key":"2022031220110196500_B143","first-page":"205","article-title":"A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers","volume":"42","author":"Huang","year":"2015","journal-title":"Undersea Hyperb Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/Supplement_1\/S105\/549357\/dc18s010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/Supplement_1\/S105\/549357\/dc18s010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:00:05Z","timestamp":1647104405000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/Supplement_1\/S105\/29707\/10-Microvascular-Complications-and-Foot-Care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":143,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-s010","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]}}}